KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Return on Equity (2021 - 2023)

Historic Return on Equity for AbCellera Biologics (ABCL) over the last 4 years, with Q3 2024 value amounting to 0.04%.

  • AbCellera Biologics' Return on Equity rose 700.0% to 0.04% in Q3 2024 from the same period last year, while for Sep 2024 it was 0.04%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 0.15% for FY2024, which is 200.0% down from last year.
  • As of Q3 2024, AbCellera Biologics' Return on Equity stood at 0.04%, which was up 700.0% from 0.07% recorded in Q2 2024.
  • In the past 5 years, AbCellera Biologics' Return on Equity ranged from a high of 0.32% in Q1 2021 and a low of 0.13% during Q4 2023
  • Over the past 4 years, AbCellera Biologics' median Return on Equity value was 0.13% (recorded in 2022), while the average stood at 0.08%.
  • Per our database at Business Quant, AbCellera Biologics' Return on Equity tumbled by -3100bps in 2023 and then soared by 700bps in 2024.
  • Quarter analysis of 4 years shows AbCellera Biologics' Return on Equity stood at 0.16% in 2021, then dropped by -18bps to 0.13% in 2022, then tumbled by -198bps to 0.13% in 2023, then skyrocketed by 66bps to 0.04% in 2024.
  • Its Return on Equity stands at 0.04% for Q3 2024, versus 0.07% for Q2 2024 and 0.09% for Q1 2024.